Clinical Trial Search

Primary: Rate of Patients Alive and Progression-free 6 Months After Inclusion. — 22 Nb of patients alive without progression

Primary: Maximum Plasma Concentration (Cmax) of Pexidartinib Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants — 1420…

Primary: Progression-free Survival Rate After 1 Course of Treatment — 48; 59 percentage of participants — p=0.05

Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death — 57; 54; 255; 0 Participants

Primary: Absolute Perihematoma Edema (aPHE) Volume Measured by Computed Tomography (CT) Scan After Intracerebral Hemorrhage (ICH) — 55.09; 52.50 mL — p=0.585

Primary: AUC0-tz of BI 1467335 — 3.90; 2.24; 2.49 nanomole*hour/Liter (nmol*h/L)

Primary: Number of Subjects With Investigator Defined Drug-related Adverse Events — 3; 4; 6; 4 Participants

Primary: Maximum Nicotine Concentration in Blood — 3.6; 5.3; 4.0; 5.3 ng/mL

Primary: Fraction of [14C]-Radioactivity Excreted in Urine as Percentage of the Administered Oral Dose Over the Time Interval From 0 to the Last Quantifiable Time Point…

Primary: Fractional Flow Reserve (FFR) — 0.862; 0.863 Ratio

Primary: Composite Assessment of Function and Survival (CAFS) at 12 Months — 438.84; 441.76 units on a scale — p=0.8568

Primary: Fraud Detection Post Training — 90.42; 85.84; 84.88; 84.32 % confidence fraudulent item is fraud

Primary: Absolute Body Weight (BW) — 104.7; 117.9 kilogram — p=<0.002

Primary: Number of Participants With Improved Skin Moisturization — 114 Participants

Primary: Percentage of Readings Within 20% Agreement — 88.00; 87.96; 84.59; 81.05 Percentage of Readings — p=<0.041